



Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00


Customer: Rogue Biosciences
Product identity: NDT20001-HH

Client/Metrc ID:

11012000

Laboratory ID: 20-002237-0001

Summary



Pesticides:

All analytes passing and less than LOQ.

Microbiology:

Less than LOQ for all analytes.





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Customer: Rogue Biosciences

Product identity: NDT20001-HH

Client/Metrc ID:

Sample Date:

Laboratory ID: 20-002237-0001

Relinquished by: UPS
Temp: 20.7 °C

Sample Results

| Potency | Method J AOAC | 2015 V98-6 | | Units % | Batch 2002014 | Analyze 03/02/20 | 11:59 PM |
|---------------------------------|---------------|------------------|-------|---------|---------------|-------------------------|------------------------|
| Analyte | | ry LOQ veight | Notes | | | | |
| CBC [†] | < LOQ | 0.0892 | | | | | CBD |
| CBC-A [†] | < LOQ | 0.0892 | | | | | CBD-A |
| CBC-Total [†] | < LOQ | 0.167 | | | | | CBG-A |
| CBD | 55.6 | 0.892 | | | | | • CBG |
| CBD-A | 42.1 | 0.892 | | | | | |
| CBD-Total | 92.5 | 1.67 | | | | | CBDV |
| CBDV [†] | 0.232 | 0.0892 | | | | | CBDV-A |
| CBDV-A [†] | 0.181 | 0.0892 | | | | | |
| CBDV-Total [†] | 0.389 | 0.167 | | | | | |
| CBG [†] | 0.440 | 0.0892 | | | | | |
| CBG-A [†] | 1.02 | 0.0892 | | | | | |
| CBG-Total [†] | 1.34 | 0.167 | | | | | |
| CBL [†] | < LOQ | 0.0892 | | | | | |
| CBN | < LOQ | 0.0892 | | | | | |
| $\Delta 8\text{-THC}^{\dagger}$ | < LOQ | 0.0892 | | | | | |
| Δ9-THC | < LOQ | 0.0892 | | | | | |
| THC-A | < LOQ | 0.0892 | | | | | |
| THC-Total | < LOQ | 0.167 | | | | | |
| THCV [†] | < LOQ | 0.0892 | | | | | |
| THCV-A [†] | < LOQ | 0.0892 | | | | | |
| THCV-Total [†] | < LOQ | 0.167 | | | | | |

| Microbiology | | | | | | | | |
|-------------------------|--------|--------|-------|-----|---------|----------|----------------------|-------|
| Analyte | Result | Limits | Units | LOQ | Batch | Analyze | Method | Notes |
| Mold (RAPID Petrifilm) | < LOQ | | cfu/g | 10 | 2001857 | 02/29/20 | AOAC 2014.05 (RAPID) | X |
| Yeast (RAPID Petrifilm) | < LOQ | | cfu/g | 10 | 2001857 | 02/29/20 | AOAC 2014.05 (RAPID) | X |





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

| Pesticides | Method | AOAC | 2007.01 & EN | 15662 (mod) | Units mg/kg Ba | tch 2001936 | Analy | ze 02/29/20 10:02 AM |
|------------------|--------|--------|--------------|-------------|---------------------|-------------|--------|----------------------|
| Analyte | Result | Limits | LOQ Status | Notes | Analyte | Result | Limits | LOQ Status Notes |
| Abamectin | < LOQ | 0.50 | 0.250 pass | | Acephate | < LOQ | 0.40 | 0.250 pass |
| Acequinocyl | < LOQ | 2.0 | 1.00 pass | | Acetamiprid | < LOQ | 0.20 | 0.100 pass |
| Aldicarb | < LOQ | 0.40 | 0.200 pass | | Azoxystrobin | < LOQ | 0.20 | 0.100 pass |
| Bifenazate | < LOQ | 0.20 | 0.100 pass | | Bifenthrin | < LOQ | 0.20 | 0.100 pass |
| Boscalid | < LOQ | 0.40 | 0.200 pass | | Carbaryl | < LOQ | 0.20 | 0.100 pass |
| Carbofuran | < LOQ | 0.20 | 0.100 pass | | Chlorantraniliprole | < LOQ | 0.20 | 0.100 pass |
| Chlorfenapyr | < LOQ | 1.0 | 0.500 pass | | Chlorpyrifos | < LOQ | 0.20 | 0.100 pass |
| Clofentezine | < LOQ | 0.20 | 0.100 pass | | Cyfluthrin | < LOQ | 1.0 | 0.500 pass |
| Cypermethrin | < LOQ | 1.0 | 0.500 pass | | Daminozide | < LOQ | 1.0 | 0.500 pass |
| Diazinon | < LOQ | 0.20 | 0.100 pass | | Dichlorvos | < LOQ | 1.0 | 0.500 pass |
| Dimethoate | < LOQ | 0.20 | 0.100 pass | | Ethoprophos | < LOQ | 0.20 | 0.100 pass |
| Etofenprox | < LOQ | 0.40 | 0.200 pass | | Etoxazole | < LOQ | 0.20 | 0.100 pass |
| Fenoxycarb | < LOQ | 0.20 | 0.100 pass | | Fenpyroximate | < LOQ | 0.40 | 0.200 pass |
| Fipronil | < LOQ | 0.40 | 0.200 pass | | Flonicamid | < LOQ | 1.0 | 0.400 pass |
| Fludioxonil | < LOQ | 0.40 | 0.200 pass | | Hexythiazox | < LOQ | 1.0 | 0.400 pass |
| Imazalil | < LOQ | 0.20 | 0.100 pass | | Imidacloprid | < LOQ | 0.40 | 0.200 pass |
| Kresoxim-methyl | < LOQ | 0.40 | 0.200 pass | | Malathion | < LOQ | 0.20 | 0.100 pass |
| Metalaxyl | < LOQ | 0.20 | 0.100 pass | | Methiocarb | < LOQ | 0.20 | 0.100 pass |
| Methomyl | < LOQ | 0.40 | 0.200 pass | | MGK-264 | < LOQ | 0.20 | 0.100 pass |
| Myclobutanil | < LOQ | 0.20 | 0.100 pass | | Naled | < LOQ | 0.50 | 0.250 pass |
| Oxamyl | < LOQ | 1.0 | 0.500 pass | | Paclobutrazole | < LOQ | 0.40 | 0.200 pass |
| Parathion-Methyl | < LOQ | 0.20 | 0.200 pass | | Permethrin | < LOQ | 0.20 | 0.100 pass |
| Phosmet | < LOQ | 0.20 | 0.100 pass | | Piperonyl butoxide | < LOQ | 2.0 | 1.00 pass |
| Prallethrin | < LOQ | 0.20 | 0.200 pass | | Propiconazole | < LOQ | 0.40 | 0.200 pass |
| Propoxur | < LOQ | 0.20 | 0.100 pass | | Pyrethrin I (total) | < LOQ | 1.0 | 0.500 pass |
| Pyridaben | < LOQ | 0.20 | 0.100 pass | | Spinosad | < LOQ | 0.20 | 0.100 pass |
| Spiromesifen | < LOQ | 0.20 | 0.100 pass | | Spirotetramat | < LOQ | 0.20 | 0.100 pass |
| Spiroxamine | < LOQ | 0.40 | 0.200 pass | | Tebuconazole | < LOQ | 0.40 | 0.200 pass |
| Thiacloprid | < LOQ | 0.20 | 0.100 pass | | Thiamethoxam | < LOQ | 0.20 | 0.100 pass |
| Trifloxystrobin | < LOQ | 0.20 | 0.100 pass | | | | | |





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

These test results are representative of the individual sample selected and submitted by the client.

Abbreviations

Limits: Action Levels per OAR-333-007-0400, OAR-333-007-0210, OAR-333-007-0220

Limit(s) of Quantitation (LOQ): The minimum levels, concentrations, or quantities of a target variable (e.g., target analyte) that can be reported with a specified degree of confidence.

† = Analyte not NELAP accredited.

Units of Measure

cfu/g = Colony forming units per gram mg/kg = Milligram per kilogram = parts per million (ppm) % = Percentage of sample % wt = μ g/g divided by 10,000

Glossary of Qualifiers

X: Not ORELAP accredited.

Approved Signatory

Derrick Tanner General Manager





Report Number:

20-002237/D02.R00

Report Date:

03/04/2020

ORELAP#:

OR100028

Purchase Order:

Received:

02/26/20 11:00

Revision: 1.02 Document Control: CF001 Revision Date: 01/14/2019 Effective Date: 01/14/2019



PIXIS Labs

12423 NE Whitaker Way Portland, OR 97230 Phone: (503) 254-1794 Fax: (503) 254-1452 www.pixislabs.com customerservice@pixislabs.com

Please inform us if you know or suspect that your sample contains hazardous chemicals.

Some or all of this analyses may be subcontracted to an ORELAP accredited lab

Chain of Custody Record

Page 1 of 3

| Company: Rogue Bioscience | | | | | | | | Testing | g Reque | sted | | | | | | |
|--------------------------------|---------------|----------------|-----------|---------|------------------------|----------|-----|---------|---------|--------|--------|-------|---|--------------------------------|-------|---|
| Contact: Anthony DeLuca | | | | | ÷ | | | | | | | | | Purchase Ord | | |
| Street: 189 Ehrman Way OR 9 | 97520 | | | | as | | | | | | | | | | | |
| City,State,Zip: Medford OR 97 | 7501 | | | | \\ | | | | | | | | 1 | Project Name: | | |
| Email: testresults@emeraldfa | amilyhemp.com | | | | 용 | | | | | | | | | □ Report Instru | | |
| Phone: (541) 973-2040 | Fax: (|) | | | E | | | | | | | | | □ State Compl □ Email Final | | mat/Send to State |
| Billing (if different): | | | | 5 | bial | sticides | | | | | | | | | | 0 Auth/Check # |
| Client Sample Identifi | ication | Date/ Colle | | Potency | Microbial (mold/yeast) | Pestic | | | | | | | | Sample Type | # Cnr | Comments |
| √ NDT20001-HH | | 2/25/20 | 9:45 | х | х | х | | | | | | | c | oil | 1 | 2.5 grams / non detect THC oil formulated with 40%CBDa/60%CBD |
| VNDT20002-SSC | | ' | 1 | х | х | х | | | | | | | ' | | 2 | 1 |
| NDT20003-CC | | ' | ' | х | х | x | | | | | | | ' | | 3 | ı |
| NDT20004-L | | 1 | ' | х | х | х | | | | | | | ' | | 4 | ı |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| Sampled by: Anthony De | Luca * Reli | nquished b | y (Signat | ure) | Date | e | Tim | e | Recei | ved by | (Signa | ture) | | Date | Time | Lab Use Only: Client Alias: |
| Turn-around time: | a | ull | 21 | | 2/24 | 1/20 | ド | 0,5 | Had | rit | Ale | gn | | 2-26-20 | 11:00 | Job No: |
| Ask for availability | | | | | | | | | / | | | | | | | □Proper Container |
| ☑ Standard | | 4m | | | _ | | | | | | | | | | | □Sample Condition |
| ☐ Rush (1.5 Times Standard) | | | | | - | | | | | | | | | | | □Temperature 4 ± 2 °C 25. T |
| ☐ Priority Rush (2 Times Stand | dard) | | | | | | | | | | | | | | | Evidence of Cooling □Yes ■ No |
| | | | | | | | | | | | | | | | | Shipped Via: UPS |

*SUBMISSION OF SAMPLES WITH TESTING REQUIREMENTS TO PIXIS LABS WILL BE UNDERSTOOD TO BE AN AGREEMENT FOR SERVICES IN ACCORDANCE WITH THE CONDITIONS LISTED ON THE BACK OF THIS FORM. BY SIGNING "RELIQUISHED BY" YOU AGREE TO THESE TERMS AND CONDITIONS.





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 ORELAP#: OR100028

Purchase Order:

Received: 02/26/20 11:00

COMPANY NAME

Revision: 1.00 Document Control: CF001 Revision Date: 04/28/2018 Effective Date: 04/28/2018

PIXIS Labs CHAIN OF CUSTODY INSTRUCTIONS

Name of the company and/or individual who will receive the lab report. Please specify if the billing information is

and CONTACT INFO different than the reporting information.

COMMENTS -A brief description of any special instructions pertaining to the samples or reporting.

PO# -Applies to a customer purchase order or number to be listed on the invoice. PROJECT -Applies to a customer project name or number to be listed on the report

Applies to report format. MUST BE CHECKED FOR ALL COMPLIANCE WORK REQUESTED. All samp STATE COMPLIANCE -

must be collected and preserved properly. A job may be rejected if it does not meet State or NELAC standards.

Refer to sampling instruction sheets.

CLIENT SAMPLE ID -A short description of the sample point or material to be analyzed (e.g., "Effluent from sand filter"). This description will

appear on the report.

COLLECTION DATE -The date on which the sample(s) was/were collected. COLLECTION TIME -The time at which the sample(s) was/were collected.

SAMPLE TYPE -This is a description of the sample media (e.g., drinking water, waste water, soil, etc.) TESTING REQUESTED -Use one line for each analysis or group of analyses associated to a specific sample ID.

SAMPLED BY -The name of the person who collected the sample(s).

RELINQUISHED BY -The signature of the person who is turning possession of the sample(s) to the lab for analysis along with date and time. All

below terms and conditions are agreed upon this signature.

RECEIVED BY -The lab personnel who receives the sample(s) signs here and fills in the date/time received. The date and

time should be same as "Relinquished by" unless the sample(s) was shipped.

TERMS AND CONDITIONS

PRICING AND CHARGES

PRICING AND CHARGES

Prices to be charged for work performed for CUSTOMER are those currently published in the Columbia Food Laboratories, Inc. DBA Pixis Labs (herein referred to as "the LAB", where Columbia Food Laboratories, Inc. & Pixis Labs can be used interchangeably) standard price book unless otherwise agreed in writing by the CUSTOMER and the LAB. CUSTOMER must notify the LAB of price quotation at the time of the transfer of sample(s) to the LAB. Any cancellation of testing requirements will result in charges being assessed on all testing completed prior to the notice of cancellation. Unless otherwise agreed upon, samples containing hazardous material will be shipped back to client at their expense, or disposed of at a certain fee, waste category dependent. New accounts are accepted with full payment in advance by cash, check, Visa or Mastercard. A credit line may be established with an approved credit application.

DELIVERY AND LIABILITY LIMITATIONS

The specific format of the goods will be defined by CUSTOMER to the LAB upon delivery of the sample(s) to the LAB. The LAB will analyze samples provided by CUSTOMER as requested by CUSTOMER in accordance with the procedures documented in the Quality Assurance Plan (QAP). Samples are retained for 15 days. If additional time is desired, then a written request is required and an additional monthly fee will apply. This price quote is only valid for one year after initial quote date.

CONFIDENTIALITY
The LAB will treat all information regarding work performed for CUSTOMER as proprietary and confidential. No CUSTOMER information will be released to third persons without the written request of the CUSTOMER.

LIMITATION OF LIABILITY AND WARRANTY
The LAB gives no warranty, express or implied, or of fitness for a particular purpose, in connection with its analytical testing or reporting. Any liability of the LAB to CUSTOMER or any third party shall be limited to the cost of analysis charged to CUSTOMER.

PAST DUE ACCOUNTS

Credit line account are payable within 30 days. Accounts that are 60 days past due will incur 11/2% per month on all past due sums until paid in full and will automatically default to cash on delivery (COD). Reports will not be released unless payment on past and current invoices are received. Customer agrees to pay the interest as a service charge and all the LAB's collection costs, including reasonable attorney fees.

EXPERT TESTIMONY AND COURT APPEARANCES

In the event CUSTOMER requires the further written opinion or testimony of any employee of the LAB, including response to a subpoena issued by CUSTOMER or any third person, CUSTOMER agrees to pay such additional fees and expenses as may be reasonably assessed by the LAB.

ALTERNATIVE DISPUTE RESOLUTION (ADR)

Any disputes arising out of this Agreement or the analytical testing or reporting by the LAB shall be settled through mediation and/or arbitration rather than litigation, and the cost of the ADR shall be borne equally by both parties.

APPLICABLE LAW
Legal matters arising from work performed by the LAB for CUSTOMER will be construed and interpreted in accordance with the laws for the state of Oregon.





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00



Columbia Food/Pixis Labs Sample Receipt Form Revision: 1.00 Document Control: CF015 Revised: 04/25/2019 Effective: 05/11/2019

| Job Number: 20-002237 Search Name: | | | | |
|--|----------|----------|--------|----|
| Package/Cooler opened on (if different than received date/time) Date: 26 - W | Time: _ | 11:00 | | |
| Received By (Initials): | | | | |
| Were custody seals on outside of the package/cooler? If YES, how many and where? | YES | NO | NA | |
| Were signature and date correct? | YES | NO | NA | |
| 2) Were custody papers included in the package/cooler? | YES | NO | NA | |
| 3) Were custody papers properly filled out (ink, sign, date)? | YES | NO | NA | |
| 4) Did you sign custody papers in the appropriate place? | YES | NO | NA | |
| 5) How was the package/cooler delivered? | | | | |
| FEDEX USPS CLIENT COURIER | OTHE | ER: | | _ |
| Tracking Number (written in or copy of shipping label): 12 739 | WVI | 0 | 1259 | 78 |
| 6) Was packing material used? | YES | NO | NA | |
| Peanuts Bubble Wrap Foam Paper Other: | | | | |
| 7) Was sufficient ice used (if appropriate)? What kind? | YES | NO | NA | |
| Blue Ice Cooler Packs Dry Ice | | | | |
| 8) Were all sample containers sealed in separate plastic bags? | YES | NO | NA | |
| 9) Did all sample containers arrive in good condition? | YES | NO | NA | |
| 10) Were all sample container labels complete? | VES | NO | NA | |
| 11) Did all sample container labels and tags agree with the coc? | YES | NO | NA | |
| 12) Were correct sample containers used for the tests indicated? | YES | NO | NA | |
| 13) Were VOA vials checked for absence of air bubbles (note if found)? | YES | NO | NA | |
| 14) Was a sufficient amount of sample sent in each sample container? | YES | NO | NA | |
| 15) Temperature of the samples upon receipt (See SOP for proper temps) | 20. | 1_°(| | |
| 16) Sample location prior to login: R25 R39 R44 F44 Ambient She | If Canna | ıbis Tal | Other: | |
| Explain any discrepancies: | | | | |

www.columbialaboratories.com

Page 7 of 12





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Revision: 1.00 Control: CFL-C21 Revised: 08/12/2019 Effective: 08/15/2019

Laboratory Pesticide Quality Control Results

| AOAC 2007.1 & EN 1566 | 2 | Units | : mg/Kg | | | Ba | tch ID: 200193 | 6 |
|-----------------------|--------------|--------------|---------|----------------|-----------|-----------|----------------|-------|
| wemoa siank | | | | Laboratory Con | | | | |
| Analyte | Blank Result | Blank Limits | Notes | LCS Result | LCS Spike | LCS % Rec | Limits | Notes |
| Acephate | 0.000 | < 0.200 | | 0.779 | 1.000 | 77.9 | 69.3 - 129 | |
| Acequinocyl | 0.065 | < 1.000 | | 3.894 | 4.000 | 97.3 | 69.8 - 130 | |
| Acetamiprid | 0.000 | < 0.100 | 1 | 0.389 | 0.400 | 97.2 | 70.3 - 131 | |
| Aldicarb | 0.000 | < 0.200 | | 0.768 | 0.800 | 96.0 | 70.3 - 131 | |
| Abamectin | 0.053 | < 0.288 | 1 | 0.947 | 1.000 | 94.7 | 70.5 - 131 | |
| Azoxystrobin | 0.011 | < 0.100 | 1 | 0.384 | 0.400 | 96.0 | 71.4 - 133 | |
| Bifenazate | 0.012 | < 0.100 | | 0.397 | 0.400 | 99.3 | 71.3 - 132 | |
| Bifenthrin | 0.012 | < 0.100 | 1 | 0.361 | 0.400 | 90.2 | 70.7 - 131 | |
| Boscalid | 0.021 | < 0.100 | | 0.848 | 0.800 | 106.0 | 70.9 - 132 | |
| Carbaryl | 0.014 | < 0.100 | 1 | 0.382 | 0.400 | 95.4 | 70.8 - 132 | |
| Carbofuran | 0.004 | < 0.100 | 1 | 0.397 | 0.400 | 99.4 | 72.6 - 135 | |
| Chlorantraniliprol | 0.010 | < 0.100 | 1 | 0.385 | 0.400 | 96.3 | 69.3 - 129 | |
| Chlorfenapyr | 0.332 | < 1.000 | | 2.560 | 2.000 | 128.0 | 70.8 - 132 | |
| Chlorpyrifos | 0.000 | < 0.100 | 1 | 0.364 | 0.400 | 90.9 | 71.2 - 132 | |
| Clofentezine | 0.011 | < 0.100 | | 0.375 | 0.400 | 93.9 | 68.1 - 126 | |
| Cyfluthrin | 0.103 | < 1.000 | | 2.166 | 2.000 | 108.3 | 70.5 - 131 | |
| Cypermethrin | 0.135 | < 1.000 | | 1.938 | 2.000 | 96.9 | 72.2 - 134 | |
| Daminozide | 0.000 | < 1.000 | | 2.007 | 2.000 | 100.3 | 68.1 - 127 | |
| Diazinon | 0.010 | < 0.100 | | 0.384 | 0.400 | 96.1 | 70.9 - 132 | |
| Dichlorvos | 0.000 | < 0.500 | | 2.057 | 2.000 | 102.9 | 69.1 - 128 | |
| Dimethoat | 0.007 | < 0.100 | | 0.385 | 0.400 | 96.4 | 70.1 - 130 | I |
| Ethoprophos | 0.009 | < 0.100 | | 0.393 | 0.400 | 98.3 | 68.6 - 127 | |
| Etofenprox | 0.001 | < 0.100 | | 0.791 | 0.800 | 98.9 | 73.6 - 137 | |
| Etoxazol | 0.011 | < 0.100 | | 0.376 | 0.400 | 93.9 | 71.3 - 132 | |
| Fenoxycarb | 0.003 | < 0.100 | I | 0.390 | 0.400 | 97.5 | 70.9 - 132 | Ī |
| Fenpyroximat | 0.016 | < 0.100 | | 0.781 | 0.800 | 97.6 | 71.8 - 133 | |
| Fipronil | 0.028 | < 0.100 | 1 | 0.771 | 0.800 | 96.4 | 71.2 - 132 | |
| Flonicamid | 0.062 | < 0.400 | 1 | 0.984 | 1.000 | 98.4 | 69.4 - 129 | |
| Fludioxonil | 0.000 | < 0.100 | | 0.912 | 0.800 | 114.0 | 73.5 - 137 | |
| Hexythiazox | 0.022 | < 0.400 | 1 | 0.930 | 1.000 | 93.0 | 71.7 - 133 | |
| mazalil | 0.016 | < 0.100 | | 0.394 | 0.400 | 98.6 | 72.9 - 135 | |
| Imidacloprid | 0.039 | < 0.200 | 1 | 0.758 | 0.800 | 94.7 | 69.9 - 130 | |
| Kresoxim-Methyl | 0.000 | < 0.100 | | 0.865 | 0.800 | 108.1 | 71.4 - 133 | |
| Malathion | 0.004 | < 0.100 | | 0.403 | 0.400 | 100.8 | 70.9 - 132 | |
| Metalaxyl | 0.007 | < 0.100 | 1 | 0.389 | 0.400 | 97.4 | 70.5 - 131 | |
| Methiocarb | 0.004 | < 0.100 | | 0.387 | 0.400 | 96.6 | 70.8 - 132 | |
| Methomyl | 0.046 | < 0.200 | 1 | 0.778 | 0.800 | 97.2 | 68.7 - 128 | |
| MGK 264 | 0.013 | < 0.100 | 1 | 0.404 | 0.400 | 100.9 | 70.6 - 131 | 1 |
| Myclobutanil | 0.000 | < 0.100 | 1 | 0.377 | 0.400 | 94.2 | 70.4 - 131 | |
| Naled | 0.026 | < 0.200 | 1 | 0.982 | 1.000 | 98.2 | 71.6 - 133 | |
| Oxamyl | 0.000 | < 0.400 | 1 | 2.005 | 2.000 | 100.3 | 68.5 - 127 | |
| Paclobutrazol | 0.005 | < 0.200 | 1 | 0.773 | 0.800 | 96.6 | 71.6 - 133 | |
| Parathion Methyl | 0.000 | < 0.200 | 1 | 0.794 | 0.800 | 99.3 | 71.8 - 133 | |
| Permethrin | 0.015 | < 0.100 | 1 | 0.388 | 0.400 | 97.0 | 74.2 - 138 | 1 |
| Phosmet | 0.006 | < 0.100 | 1 | 0.393 | 0.400 | 98.2 | 71.0 - 132 | |
| Piperonyl butoxide | 0.000 | < 1.000 | 1 | 2.099 | 2.000 | 104.9 | 75.3 - 140 | t |
| Prallethrin | 0.035 | < 0.200 | 1 | 0.372 | 0.400 | 92.9 | 71.9 - 134 | |
| Propiconazole | 0.000 | < 0.200 | 1 | 0.782 | 0.800 | 97.7 | 70.9 - 132 | |
| ropoxur | 0.008 | < 0.100 | t e | 0.374 | 0.400 | 93.6 | 71.1 - 132 | |
| yrethrins | 0.008 | < 0.500 | 1 | 0.360 | 0.413 | 87.1 | 74.8 - 139 | |
| Pyridaben | 0.000 | < 0.100 | 1 | 0.379 | 0.400 | 94.9 | 78.0 - 145 | |
| Spinosad | 0.001 | < 0.100 | 1 | 0.405 | 0.388 | 104.4 | 74.3 - 138 | |
| piromesifen | 0.004 | < 0.100 | 1 | 0.408 | 0.400 | 102.0 | 71.5 - 133 | |
| Spirotetramat | 0.010 | < 0.100 | 1 | 0.401 | 0.400 | 100.2 | 70.1 - 130 | |
| piroxamine | 0.026 | < 0.100 | 1 | 0.791 | 0.800 | 98.8 | 72.8 - 135 | |
| Tebuconazol | 0.016 | < 0.200 | 1 | 0.810 | 0.800 | 101.2 | 71.1 - 132 | 1 |
| hiacloprid | 0.000 | < 0.100 | 1 | 0.388 | 0.400 | 96.9 | 70.7 - 131 | 1 |
| Thiamethoxam | 0.030 | < 0.100 | 1 | 0.434 | 0.400 | 108.5 | 69.9 - 130 | |
| Trifloxystrobin | 0.000 | < 0.100 | 1 | 0.400 | 0.400 | 99.9 | 71.5 - 133 | 1 |





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Revision: 1.00 Control: CFL-C21 Revised: 08/12/2019 Effective: 08/15/2019

Laboratory Pesticide Quality Control Results

| Matrix Spike (Matrix Spike Duplicate Recoveries MSD Res Smyle RPO% Limit MS Res MSD Res Limit MS Res Limit MS Res MSD Res Limit MS Res Limit Limit MS Res Limit | 11936 | tch ID: 2001936 | Rati | resuits | HILIOI | iity Co | | y Pestici Units: | DOTALOT | La | AOAC 2007.1 & EN 15662 |
|--|----------|-----------------|-------|------------|--------|---------|--------------|---------------------|---|-----------------|--|
| Analyte | ACCOUNT. | | | Sample ID: | | | 0110 | | eries | uplicate Recove | |
| Acephate | s Notes | | | | Limit | RPD% | Spike | MSD Res | | | |
| Acetamprid O.000 O.000 O.000 O.000 O.000 O.000 O.000 O.000 O.0000 O.000 O.0000 O.0000 O.0000 O.0000 O.0000 O.0000 O.0000 O.0000 O.00 | 150 | 50 - 150 | 81.1 | 80.7 | < 30 | 0.6 | 1.000 | 0.811 | 0.807 | 0.000 | Acephate |
| Malcach | 150 | 50 - 150 | 111.0 | 108.3 | < 30 | 2.5 | 4.000 | 4.438 | 4.331 | 0.000 | Acequinocyl |
| Namerin 0.046 | 150 | 50 - 150 | 96.6 | 100.4 | < 30 | 3.9 | 0.400 | 0.386 | 0.402 | 0.000 | Acetamiprid |
| Name | 150 | 50 - 150 | 98.9 | 99.4 | < 30 | 0.4 | 0.800 | 0.791 | 0.795 | 0.000 | Aldicarb |
| Silenazate | 150 | 50 - 150 | 97.3 | 99.7 | < 30 | 2.3 | 1.000 | 1.019 | 1.043 | 0.046 | Abamectin |
| Selenthrin | 150 | 50 - 150 | 87.6 | 89.0 | < 30 | 1.6 | 0.400 | 0.360 | 0.365 | 0.009 | Azoxystrobin |
| Boscalid | 150 | 50 - 150 | 91.9 | 91.1 | < 30 | 0.9 | 0.400 | 0.377 | 0.374 | 0.010 | Bifenazate |
| Carbaryl 0.013 0.394 0.389 0.400 1.3 < 0.0 95.2 94.0 50 - 2. abrofuran 0.004 0.398 0.399 0.400 0.3 < 0.0 95.2 94.0 50 - 2. abrofuran 0.004 0.398 0.399 0.400 3.1 < 30 98.5 98.8 50 - 2. abrofuran 0.000 0.308 0.359 0.370 0.400 3.1 < 30 87.7 90.5 50 - 2. abrofuran 0.000 0.214 1.818 0.200 19.6 < 30 110.7 90.9 50 - 2. abrofuran 0.000 0.462 0.436 0.400 6.0 < 3.0 110.7 90.9 50 - 2. abrofuran 0.000 0.462 0.436 0.400 4.0 < 4.2 < 30 114.9 107.2 50 - 2. abrofuran 0.000 0.428 0.410 0.400 4.2 < 30 114.9 107.2 50 - 2. abrofuran 0.000 1.756 1.701 2.000 3.2 < 30 99.4 100.9 50 - 2. abrofuran 0.000 1.756 1.701 2.000 3.2 < 30 99.4 100.9 50 - 2. abrofuran 0.000 1.756 1.701 2.000 3.2 < 30 99.4 100.9 50 - 2. abrofuran 0.000 0.000 1.756 1.701 2.000 3.1 < 30 87.8 85.1 30 - 2. abrofuran 0.000 0.000 1.756 1.701 2.000 3.1 < 30 87.8 85.1 30 - 2. abrofuran 0.000 0.000 0.387 0.391 0.400 2.3 < 30 99.9 4 100.9 90.6 50 - 2. abrofuran 0.000 0.000 0.387 0.391 0.400 1.0 < 30 99.9 97.6 50 - 2. abrofuran 0.000 0.000 0.387 0.391 0.400 1.0 < 30 95.2 96.2 50 - 2. abrofuran 0.000 0.000 0.387 0.391 0.400 1.0 < 30 95.2 96.2 50 - 2. abrofuran 0.000 0 | 150 Q1 | 50 - 150 | 199.1 | 200.7 | < 30 | 0.8 | 0.400 | 0.821 | 0.827 | 0.025 | Bifenthrin |
| Carbofuran 0.004 0.388 0.399 0.400 0.3 < 30 985 98.8 50 0.10 | 150 | 50 - 150 | 103.4 | 96.0 | < 30 | 7.2 | 0.800 | 0.850 | 0.791 | 0.022 | Boscalid |
| Chloratraniliprol 0.008 | 150 | 50 - 150 | 94.0 | 95.2 | < 30 | 1.3 | 0.400 | 0.389 | 0.394 | 0.013 | Carbaryl |
| Chlorfenapyr | 150 | 50 - 150 | 98.8 | 98.5 | < 30 | 0.3 | 0.400 | 0.399 | 0.398 | 0.004 | Carbofuran |
| Chorpyrifos | 150 | 50 - 150 | 90.5 | 87.7 | < 30 | 3.1 | 0.400 | 0.370 | 0.359 | 0.008 | Chlorantraniliprol |
| Clefentezizene | 150 | 50 - 150 | 90.9 | 110.7 | < 30 | 19.6 | 2.000 | 1.818 | 2.214 | 0.000 | Chlorfenapyr |
| Alluthrin | 150 | 50 - 150 | 107.2 | 113.9 | < 30 | 6.0 | 0.400 | 0.436 | 0.462 | 0.007 | Chlorpyrifos |
| Sypermethrin | 150 | 50 - 150 | 100.2 | 104.6 | < 30 | 4.2 | 0.400 | 0.410 | 0.428 | 0.010 | Clofentezine |
| Daminozide 0.000 | 150 | 30 - 150 | 83.0 | 79.1 | < 30 | 4.5 | 2.000 | 1.742 | 1.664 | 0.082 | Cyfluthrin |
| Daminozide 0.000 | 150 | 50 - 150 | 102.9 | 99.4 | < 30 | 3.2 | 2.000 | 2.170 | 2.101 | 0.112 | Cypermethrin |
| Dichloros 0.001 2.111 2.172 2.000 2.8 < 30 105.5 108.6 50 Dimethoat 0.006 0.387 0.391 0.400 1.0 < 30 | | | | 87.8 | < 30 | 3.1 | 2.000 | | | | |
| Dichloros 0.001 2.111 2.172 2.000 2.8 < 30 105.5 108.6 50 Dimethoat 0.006 0.387 0.391 0.400 1.0 < 30 | 150 | 50 - 150 | 97.6 | 99.9 | < 30 | 2.3 | 0.400 | 0.399 | 0.408 | 0.009 | Diazinon |
| Ethoprophos 0.038 0.433 0.433 0.430 0.400 0.00 0.00 0.005 0.865 0.843 0.800 0.25 0.30 107.5 104.9 50 | | | | | | | | | | | |
| Ethoprophos 0.038 0.433 0.433 0.430 0.400 0.00 0.00 0.005 0.865 0.843 0.800 0.25 0.30 107.5 104.9 50 | | | | | | | | | | | |
| Etoxazol | 150 | 50 - 150 | 98.8 | 98.8 | < 30 | 0.0 | 0.400 | 0.433 | 0.433 | 0.038 | Ethoprophos |
| Femotycarb 0.002 | 150 | 50 - 150 | 104.9 | 107.5 | < 30 | 2.5 | 0.800 | 0.843 | 0.865 | 0.005 | Etofenprox |
| Penpyroximat | 150 | 50 - 150 | 97.3 | 106.2 | < 30 | 8.7 | 0.400 | 0.393 | 0.429 | 0.004 | toxazol |
| Ferrigoroximat | 150 | 50 - 150 | 96.7 | 98.7 | < 30 | 2.1 | 0.400 | 0.389 | 0.397 | 0.002 | enoxycarb |
| Improvided Color | 150 | | 94.6 | 95.0 | < 30 | 0.4 | 0.800 | 0.757 | 0.760 | 0.000 | enpyroximat |
| Forestriangle Color Colo | 150 | 50 - 150 | 98.4 | 103.4 | < 30 | 4.7 | 0.800 | 0.815 | 0.854 | 0.027 | |
| Heleythazox | 150 | 50 - 150 | 92.1 | 92.9 | < 30 | 0.8 | 1.000 | 0.973 | 0.981 | 0.052 | Flonicamid |
| Heleythazox | 150 | 50 - 150 | 105.2 | 99.3 | < 30 | 5.8 | 0.800 | 0.842 | 0.794 | 0.000 | Fludioxonil |
| mazall | 150 | 50 - 150 | | 134.6 | | 1.6 | 1.000 | | | | Hexythiazox |
| Gresoxim Methyl 0.000 0.743 0.767 0.800 3.2 < 30 92.9 95.9 50 Malathion 0.000 0.382 0.387 0.400 1.3 < 30 95.5 96.7 50 - Methion 0.000 0.412 0.387 0.400 6.1 < 30 10.15 95.4 50 - Methodrath 0.002 0.412 0.417 0.400 6.1 2.30 10.25 103.8 50 - McKrod4 0.013 0.448 0.491 0.400 9.1 < 30 102.5 103.8 50 - McKrod4 0.013 0.448 0.491 0.400 9.1 < 30 108.9 119.6 50 - Myclobutanil 0.000 0.392 0.383 0.400 2.4 < 30 98.1 95.7 50 - Asled 0.002 2.034 1.858 2.000 9.0 < 30 101.7 92 | 150 | | 90.9 | 97.5 | < 30 | 6.7 | 0.400 | 0.376 | 0.402 | 0.013 | mazalil |
| Kresoxim-Methyl 0.000 0.743 0.767 0.800 3.2 2.30 92.9 95.9 50 - Malathion Malathion 0.000 0.382 0.387 0.400 6.1 < 30 | 150 | 50 - 150 | 94.0 | 94.7 | < 30 | 0.7 | 0.800 | 0.786 | 0.792 | 0.034 | midacloprid |
| Malathion 0.000 0.382 0.387 0.400 1.3 < 30 95.5 96.7 50 - Metalaxyl 0.006 0.412 0.387 0.400 6.1 < 30 | 150 | 50 - 150 | 95.9 | 92.9 | < 30 | 3.2 | 0.800 | | 0.743 | 0.000 | |
| Methiccarb 0.002 0.412 0.417 0.400 1.2 < 30 102.5 103.8 50 Methomyl 0.040 0.773 0.754 0.800 2.6 < 30 | 150 | | 96.7 | 95.5 | < 30 | 1.3 | 0.400 | 0.387 | 0.382 | 0.000 | Malathion |
| Methomyl 0.040 0.773 0.754 0.800 2.6 < 30 91.7 89.2 50 - MGK Z64 0.013 0.448 0.491 0.400 9.1 < 30 108.9 119.6 50 - Widyclobutanil 0.000 0.392 1.010 0.995 1.000 1.5 < 30 98.8 97.3 50 - Naled 0.022 1.010 0.995 1.000 1.5 < 30 98.8 97.3 50 - Acalobutrazol 0.003 3.824 0.835 0.800 1.2 < 30 98.8 97.3 50 - Parathion Methyl 0.000 0.780 0.652 0.800 17.9 < 30 97.4 81.5 30 - Permethrin 0.014 0.477 0.483 0.400 1.1 < 30 97.4 81.5 30 - Piperonyl butoxide 0.000 2.150 0.2113 2.000 1.7 | 150 | 50 - 150 | 95.4 | 101.5 | < 30 | 6.1 | 0.400 | 0.387 | 0.412 | 0.006 | Metalaxyl |
| Methomyl 0.040 0.773 0.754 0.800 2.6 < 30 91.7 89.2 50 - MGK 264 MGK 264 0.013 0.448 0.491 0.400 2.4 < 30 | 150 | 50 - 150 | 103.8 | 102.5 | < 30 | 1.2 | 0.400 | 0.417 | 0.412 | 0.002 | Methiocarb |
| Myclobatanil 0.000 0.392 0.383 0.400 2.4 <30 98.1 95.7 50 | 150 | | 89.2 | 91.7 | < 30 | 2.6 | 0.800 | 0.754 | 0.773 | | |
| Myclobatanil 0.000 0.392 0.383 0.400 2.4 <30 98.1 95.7 50 | 150 | 50 - 150 | 119.6 | 108.9 | < 30 | 9.1 | 0.400 | 0.491 | 0.448 | 0.013 | MGK 264 |
| Naled 0.022 1.010 0.995 1.000 1.5 < 30 98.8 97.3 50 - 20 | | | | | | 2.4 | | | | | |
| Deamy 0.000 2.034 1.858 2.000 9.0 <30 101.7 92.9 50 -2 | | | | | | | | | | | |
| Paciobutrazol 0.003 0.824 0.835 0.800 1.2 < 30 102.7 104.0 50 - 2 | | 10000 | | | | 9.0 | | | | | |
| Parathion Methyl 0.000 0.780 0.652 0.800 17.9 < 30 97.4 81.5 30 - Permethrin 0.014 0.477 0.483 0.400 1.1 < 30 | | | | | | | | | | | |
| Permethrin 0014 0.477 0.483 0.400 1.1 < 30 116.0 117.3 50 - 10.000 | | | | | | | | | | | |
| Phosmet 0.006 0.383 0.403 0.400 5.1 < 30 942 99.3 50 - 10 | | | | | | | | | | | |
| Prepare Prep | | | | | | | | | | | |
| Vallethrin 0.021 0.540 0.512 0.400 5.4 < 30 129.7 122.6 50 - Propiconazole 0.000 0.805 0.800 0.800 0.7 < 30 | | | | | | | | | | | |
| Propiconazole 0.000 0.805 0.800 0.800 0.7 < 30 100.6 99.9 50 - 20 20 20 20 20 20 20 20 20 20 20 20 20 | | | | | | | | | | | |
| Proposur 0.007 0.382 0.396 0.400 3.7 < 30 93.8 97.4 50 - 7 Yrethrins 0.000 0.406 0.406 0.413 0.1 < 30 | | | | | | | | | | | |
| Ayrethrins 0.000 0.406 0.406 0.413 0.1 < 30 98.3 98.2 50 - Yridaben 0.000 0.358 0.355 0.400 0.8 < 30 | | | | | | | | | | | |
| Vyridaben 0.000 0.358 0.355 0.400 0.8 < 30 89.4 88.8 50 - pinosad 0.000 0.419 0.437 0.388 4.2 < 30 | | | | | | | | | | | |
| pinosad 0,000 0,419 0,437 0,388 4,2 < 30 108,0 112,7 50 pinomesilen 0,011 0,466 0,496 0,400 6,2 < 30 113,8 121,3 50 pinomesilen 0,000 0,362 0,343 0,400 5,4 < 30 90,5 85,8 50 pinokamine 0,022 0,777 0,787 0,800 1,3 < 30 94,4 95,7 50 pinokamine 0,022 0,773 0,800 1,3 < 30 94,4 95,7 50 hacloprid 0,034 0,793 0,820 0,800 3,3 < 30 94,9 98,3 50 hacloprid 0,000 0,391 0,389 0,400 0,4 < 30 9,77 9,73 50 - | | | | | | | | | | | |
| piromesifen 0.011 0.466 0.496 0.400 6.2 < 30 113.8 121.3 50 - pirotetramat 0.000 0.362 0.343 0.400 5.4 < 30 90.5 85.8 50 - pirotetramat 0.022 0.777 0.787 0.800 1.3 < 30 94.4 95.7 50 - piebuconazol 0.034 0.793 0.820 0.800 3.3 < 30 94.4 95.7 50 - hiacloprid 0.000 0.391 0.389 0.400 0.4 < 30 97.7 97.3 50 - | | | | | | | | | | | |
| priotetramat 0.000 0.362 0.343 0.400 5.4 < 30 90.5 85.8 50 - 20 0.000 0. | | | | | | 100000 | //2/17/2/2/2 | | 100000000000000000000000000000000000000 | | MATERIAL PROPERTY AND ADDRESS OF THE PARTY AND |
| prioxamine 0.022 0.777 0.787 0.800 1.3 <.30 94.4 95.7 50 -: ebuconazol 0.034 0.793 0.820 0.800 3.3 <.30 94.9 98.3 50 -: hiacloprid 0.000 0.391 0.389 0.400 0.4 <.30 9.77 97.3 50 -: | | | | | | | | | | | |
| ebuconazol 0.034 0.793 0.820 0.800 3.3 < 30 94.9 98.3 50 - fhiacloprid 0.000 0.391 0.389 0.400 0.4 < 30 | | | | | | | | | | | |
| hiacloprid 0.000 0.391 0.389 0.400 0.4 < 30 97.7 97.3 50 - 3 | | | | | | | | | | | |
| | | | | | | | | | | | |
| Thiamethoxam 0.028 0.413 0.378 0.400 8.8 < 30 96.3 87.5 50 | | | | | | | | | | | |
| | | | | | | | | | | | |





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

Laboratory Quality Control Results

| JAOAC2015 | V986 | | | | ch ID: 2002014 | | |
|--------------|---------------|-------|-------|-------|----------------|------------|-------|
| Laboratory O | ontrol Sample | | | | | | |
| Analyte | Result | Spike | Units | % Rec | Limits | Evaluation | Notes |
| CBDV-A | 0.194 | 0.2 | % | 97.2 | 85.0 - 115 | Acceptable | |
| CBDV | 0.212 | 0.2 | % | 106 | 85.0 - 115 | Acceptable | |
| CBD-A | 0.194 | 0.2 | % | 97.1 | 85.0 - 115 | Acceptable | |
| CBG-A | 0.203 | 0.2 | % | 102 | 85.0 - 115 | Acceptable | |
| CBG | 0.202 | 0.2 | % | 101 | 85.0 - 115 | Acceptable | |
| CBD | 0.188 | 0.2 | % | 93.8 | 85.0 - 115 | Acceptable | |
| THCV | 0.196 | 0.2 | % | 97.8 | 85.0 - 115 | Acceptable | |
| THCVA | 0.196 | 0.2 | % | 97.9 | 85.0 - 115 | Acceptable | |
| CBN | 0.186 | 0.2 | % | 93.2 | 85.0 - 115 | Acceptable | |
| THC | 0.195 | 0.2 | % | 97.4 | 85.0 - 115 | Acceptable | |
| D8THC | 0.188 | 0.2 | % | 94.2 | 85.0 - 115 | Acceptable | |
| CBL | 0.192 | 0.2 | % | 96.1 | 85.0 - 115 | Acceptable | |
| CBC | 0.198 | 0.2 | % | 98.9 | 85.0 - 115 | Acceptable | |
| THCA | 0.186 | 0.2 | % | 93.2 | 85.0 - 115 | Acceptable | |
| CBCA | 0.189 | 0.2 | % | 94.5 | 85.0 - 115 | Acceptable | |

Method Blank

| Method Ban | r. | | | | | |
|------------|--|-----|-------|--------|------------|-------|
| Analyte | Result | LOQ | Units | Limits | Evaluation | Notes |
| CBDV-A | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBDV | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBD-A | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBG-A | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBG | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| CBD | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| THCV | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| THCVA | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| CBN | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| THC | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| D8THC | ⊲LOQ | 0.1 | % | < 0.1 | Acceptable | |
| CBL | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| CBC | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| THCA | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |
| CBCA | <loq< td=""><td>0.1</td><td>%</td><td>< 0.1</td><td>Acceptable</td><td></td></loq<> | 0.1 | % | < 0.1 | Acceptable | |

Abbreviations

ND - None Detected at or above MRL RPD - Relative Percent Difference

LOQ - Limit of Quantitation

Units of Measure

%- Percent





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Revision #: 0.00 Control : CFL-D06 Revision Date: 05/31/2019 Effective Date: 05/31/2019

Laboratory Quality Control Results

| JAOAC2015 V | 986 | | | | Bato | h ID: 2002014 | 4 | | | |
|----------------|---|---------------------------|-----|-------|------|---------------|------------|-------|--|--|
| Sample Duplica | ite | Sample ID: 20-002237-0001 | | | | | | | | |
| Analyte | Result | Org. Result | LOQ | Units | RPD | Limits | Evaluation | Notes | | |
| CBDV-A | 0.181 | 0.177 | 0.1 | % | 2.28 | < 20 | Acceptable | | | |
| CBDV | 0.232 | 0.227 | 0.1 | % | 2.37 | < 20 | Acceptable | | | |
| CBD-A | 42.1 | 40.8 | 0.1 | % | 3.35 | < 20 | Acceptable | | | |
| CBG-A | 1.02 | 0.998 | 0.1 | % | 2.37 | < 20 | Acceptable | | | |
| CBG | 0.440 | 0.431 | 0.1 | % | 2.08 | < 20 | Acceptable | | | |
| CBD | 55.6 | 53.8 | 0.1 | % | 3.32 | < 20 | Acceptable | | | |
| THCV | <loq< td=""><td>4.0Q</td><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| THCVA | <1.00Q | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| CBN | <loq< td=""><td>4.0Q</td><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| THC | <loq< td=""><td>4.0Q</td><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| D8THC | <loq< td=""><td>4.0Q</td><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| CBL | <loq< td=""><td>4.0Q</td><td>0.1</td><td>%</td><td>NA</td><td>< 20</td><td>Acceptable</td><td></td></loq<> | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| CBC | ⊲LOQ | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| THCA | ⊲LOQ | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |
| CBCA | ⊲LOQ | 4.0Q | 0.1 | % | NA | < 20 | Acceptable | | | |

Abbreviations

ND - None Detected at or above MRL

RPD - Relative Percent Difference

LOQ - Limit of Quantitation

NA - Calculation Not Applicable given non-numerical results

Units of Measure

%- Percent





Report Number: 20-002237/D02.R00

Report Date: 03/04/2020 **ORELAP#:** OR100028

Purchase Order:

Received: 02/26/20 11:00

Explanation of QC Flag Comments:

| Code | Explanation |
|------|---|
| Q | Matrix interferences affecting spike or surrogate recoveries. |
| Q1 | Quality control result biased high. Only non-detect samples reported. |
| Q2 | Quality control outside QC limits. Data considered estimate. |
| Q3 | Sample concentration greater than four times the amount spiked. |
| Q4 | Non-homogenous sample matrix, affecting RPD result and/or % recoveries. |
| Q5 | Spike results above calibration curve. |
| Q6 | Quality control outside QC limits. Data acceptable based on remaining QC. |
| R | Relative percent difference (RPD) outside control limit. |
| R1 | RPD non-calculable, as sample or duplicate results are less than five times the LOQ. |
| R2 | Sample replicates RPD non-calculable, as only one replicate is within the analytical range. |
| LOQ1 | Quantitation level raised due to low sample volume and/or dilution. |
| LOQ2 | Quantitaion level raised due to matrix interference. |
| В | Analyte detected in method blank, but not in associated samples. |
| B1 | The sample concentration is greater than 5 times the blank concentration. |
| B2 | The sample concentration is less than 5 times the blank concentration. |